Holen Sie sich die Stockscreener-App
58.96
4.32%
-3.06
Handel nachbörslich:
58.96
Schlusskurs vom Vortag:
$62.02
Offen:
$61.4
24-Stunden-Volumen:
2.11M
Relative Volume:
0.68
Marktkapitalisierung:
$3.23B
Einnahmen:
$14.34M
Nettoeinkommen (Verlust:
$-199.00M
KGV:
-15.04
EPS:
-3.92
Netto-Cashflow:
$-183.51M
1W Leistung:
+2.45%
1M Leistung:
+259.96%
6M Leistung:
+547.11%
1J Leistung:
+952.13%
1-Tages-Spanne:
$58.57
$61.50
1-Wochen-Bereich:
$56.08
$65.12
52-Wochen-Spanne:
$5.35
$65.12
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
58.96 | 3.82B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
Is uniQure N.V. stock trading at a premium valuationWeekly Market Summary & Real-Time Market Sentiment Reports - newser.com
Is uniQure N.V. stock a safe investment in uncertain marketsJuly 2025 Update & Low Drawdown Trading Techniques - newser.com
Can uniQure N.V. stock hit analyst price targetsEarnings Miss & Weekly Watchlist of Top Performers - newser.com
How institutional buying supports uniQure N.V. stockMarket Movers & Real-Time Chart Breakout Alerts - newser.com
What catalysts could drive uniQure N.V. stock higher2025 Top Decliners & Technical Pattern Recognition Alerts - newser.com
Using Bollinger Bands to evaluate uniQure N.V.Index Update & Technical Pattern Based Buy Signals - newser.com
uniQure N.V. stock outlook for YEARShort Setup & Long Hold Capital Preservation Plans - newser.com
uniQure N.V. $QURE Shares Purchased by Aberdeen Group plc - MarketBeat
uniQure NV Hits New 52-Week High of $61.79, Surging 1014.68% - Markets Mojo
uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is uniQure’s Rally Justified After Positive Huntington’s Disease Therapy Data? - Yahoo Finance
Jim Cramer on uniQure: “This One Has Too Many Questions for Me Up Here” - MSN
Trend analysis for uniQure N.V. this week2025 Momentum Check & Expert Verified Movement Alerts - newser.com
Will uniQure N.V. see short term momentumBreakout Watch & Verified Technical Trade Signals - newser.com
uniQure N.V. (QURE) Stock Report: A Look at Strong Buy Ratings Amidst Clinical Advancements - DirectorsTalk Interviews
Will uniQure N.V. (UQ1) stock beat value stocksDay Trade & AI Powered Market Trend Analysis - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for uniQure (NASDAQ:QURE) - MarketBeat
Is uniQure’s Stock Poised for a Comeback? - StocksToTrade
Price momentum metrics for uniQure N.V. explainedBreakout Watch & Technical Entry and Exit Tips - newser.com
Developing predictive dashboards with uniQure N.V. dataWeekly Trade Report & Verified Stock Trade Ideas - newser.com
Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind - insights.citeline.com
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood (QURE) - Seeking Alpha
uniQure NV Hits Day High with 9.47% Surge Amid Strong Intraday Performance - Markets Mojo
uniQure (NASDAQ:QURE) Sets New 12-Month HighTime to Buy? - MarketBeat
Uniqure NV stock hits 52-week high at 60.84 USD By Investing.com - Investing.com Nigeria
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $65 - 富途牛牛
Uniqure NV stock hits 52-week high at 60.84 USD - Investing.com
United States Adeno-Associated Virus (AAV) Vectors - openPR.com
HC Wainwright Analysts Lift Earnings Estimates for uniQure - MarketBeat
UniQure’s Unexpected Surge: Analyzing QURE’s Performance - timothysykes.com
uniQure (NASDAQ:QURE) Shares Up 7.7% Following Analyst Upgrade - MarketBeat
HC Wainwright Issues Positive Forecast for uniQure Earnings - MarketBeat
uniQure’s Huntington’s gene therapy holds blockbuster potential, says analyst - The Pharma Letter
Why uniQure (QURE) Is Up After Strong AMT-130 Data and $475 Million in New Funding - Sahm
uniQure (NASDAQ:QURE) Price Target Raised to $110.00 at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
uniQure stock price target raised to $110 from $70 at H.C. Wainwright - Investing.com
uniQure (QURE) Receives Boosted Price Target from HC Wainwright & Co. | QURE Stock News - GuruFocus
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $110 - 富途牛牛
Is uniQure N.V. (UQ1) stock nearing a technical breakout2025 Bull vs Bear & Consistent Return Investment Signals - newser.com
Is uniQure N.V. meeting your algorithmic filter criteriaJuly 2025 Catalysts & Smart Investment Allocation Insights - newser.com
Is uniQure N.V. showing signs of accumulation2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
Is uniQure N.V. (UQ1) stock a top dividend aristocrat candidate2025 Institutional Moves & Weekly High Return Stock Forecasts - newser.com
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Sep 24 '25 |
Sale |
41.46 |
226,316 |
9,382,473 |
651,454 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Option Exercise |
5.37 |
15,000 |
80,550 |
232,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Option Exercise |
13.03 |
3,000 |
39,090 |
220,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Sale |
55.00 |
15,000 |
825,000 |
217,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Sale |
40.04 |
3,000 |
120,120 |
217,730 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):